It can generate two signaling complexes (which we will not discuss further)

It can generate two signaling complexes (which we will not discuss further). aesthetic, genetics, scar appearance == Introduction and background == The origin of monoclonal antibodies MI 2 lies through the research work of Georges Khler and Csar Milstein in 1975 [1]. They sought to reproduce a cell line with the ability to maintain stability by secreting immunoglobulins against specific antigens indefinitely, obtained from the union of two cells through centrifugation with polyethylene glycol, a method that combines a chemical and a physical medium. Its first historical use dates back to 1982 when it was used as therapy for lymphoma. At the same time, recognition of the hyperactive effect and tolerance to human anti-murine antibodies led to the development of the process of chimerization and humanization. Monoclonal antibodies have a structure of specialized glycoproteins capable of MI 2 recognizing epitopes and developing the marking or target required for the desired purpose, among molecular biology, biotechnology, treatment of diseases, and many others [2-3]. The potential benefits through the action of these defense mechanisms can be exploited with the creation of antibodies capable of recognizing epitopes of interest for study and research. Keloid healing is a benign tumor of fibrous nature characterized by abnormal and unregulated growth of dermal fibroblasts, irregular deposition of glycosaminoglycans around the wound, low levels of hyaluronic acid, and overproduction or alteration of the extracellular matrix [4-5]. Its main difference with hypertrophic scars is the potential invasion and infiltration of surrounding tissues and an excessive expansion without quiescent periods and without a regressive phase or remodeling (they continue to develop at different speeds). Currently, the genetic factors behind the keloid scar remain under investigation. Darker-skinned individuals have a greater predisposition than lighter-skinned individuals [6]. Individuals of African origin or descent have the highest prevalence rate of 4% – 6%; however, in the adult population of Zaire, it is 16%. Asian and Hispanic descendants are less predisposed, and Caucasians have the lowest prevalence rate (as low as 0.09% in England). == Review == Antibody structure Antibodies are the surface structure of a biochemical mechanism of interaction capable of recognizing and developing actions against certain antigen epitopes. This system is made up of two heavy chains (CH) and two light chains (CL), joined by the force of disulfide bridges that will compose the antigenic recognition (Fab) and crystallizable fraction (Fc) systems in charge of antibody-dependent cell cytotoxicity (ADCC) and complement-mediated cytotoxicity (CD) [3]. Development of monoclonal antibodies The technology created by Georges Khler and Csar Milstein involved immunizing a B cell of an animal previously inoculated with the DKK1 antigen of importance to be developed to produce MI 2 the clones with the specific determinants for the antigen. The second step of interest was to extract a cell from tumor tissue, specifically, from myeloma that was unable to secrete antibodies deficient of the hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) enzyme. The immune power of the B cell was obtained by binding these two cells together to the virtually infinite division capacity of monoclonal antibodies (directed to a single epitope) or polyclonal antibodies (directed to different epitopes) whose resulting cell was named “hybridoma.” Once the hybridomas were obtained, they were placed in a special composition culture medium of hypoxanthine-aminopterin-thymidine (HAT) which allowed only the development MI 2 of the hybridomas and was ineffective for the survival of the B cell and the myeloma. It was tested for effectiveness, selecting only the desired ones, and verified their specificity by binding to the previously known antigen. Then, by the limit dilution method, cloning was performed, storing and conserving them in dimethyl sulfoxide indefinitely. The hybridomas developed by Khler and Milstein had complications since they preserved murine regions, which developed a response in the human immune system and generated tolerance to their effect. Therefore, a process called chimerization was developed in 1984: preserve only the variable murine regions and the rest of the heavy and light chains remain of human origin. Later, the process of humanization where only the hypervariable regions of the light and heavy chains were of murine origin and the rest of human origin were developed. The use MI 2 of monoclonal antibodies linked to compounds, enzymes, and pro-drugs opened a wide field of innovations and possibilities on targeted treatments [2-4]. Keloids The term keloid was originally portrayed in the 19th century as “cheloid,” acquired from the Greek word “chile,” translated to “crab claw” [7]. According to the Gauglitz et al. study published in 2011, 100 million patients developed exacerbated healing.